Publication

A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies

Partners IMBI Project, Aug-2019, In : Alzheimers & dementia. 15, 8, p. 1081-1103 23 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Partners IMBI Project (2019). A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. Alzheimers & dementia, 15(8), 1081-1103. https://doi.org/10.1016/j.jalz.2019.02.004

Author

Partners IMBI Project. / A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. In: Alzheimers & dementia. 2019 ; Vol. 15, No. 8. pp. 1081-1103.

Harvard

Partners IMBI Project 2019, 'A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies', Alzheimers & dementia, vol. 15, no. 8, pp. 1081-1103. https://doi.org/10.1016/j.jalz.2019.02.004

Standard

A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. / Partners IMBI Project.

In: Alzheimers & dementia, Vol. 15, No. 8, 08.2019, p. 1081-1103.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Partners IMBI Project. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. Alzheimers & dementia. 2019 Aug;15(8):1081-1103. https://doi.org/10.1016/j.jalz.2019.02.004


BibTeX

@article{31d7324a6cc743e18d81b70469a0330a,
title = "A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies",
abstract = "Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.",
keywords = "PET molecular imaging, Radiotracers, Protheinopathies, Amyloid, Tau, Neuroinflammation, AMYOTROPHIC-LATERAL-SCLEROSIS, ALZHEIMERS ASSOCIATION WORKGROUPS, MILD COGNITIVE IMPAIRMENT, PITTSBURGH COMPOUND-B, FRONTOTEMPORAL LOBAR DEGENERATION, 18-KDA TRANSLOCATOR PROTEIN, CEREBRAL AMYLOID ANGIOPATHY, PET TRACER F-18-AV-1451, IN-VIVO, TAU-PET",
author = "{Partners IMBI Project} and Daniela Perani and Leonardo Iaccarino and Lammertsma, {Adriaan A.} and Windhorst, {Albert D.} and Paul Edison and Ronald Boellaard and Oskar Hansson and Agneta Nordberg and Jacobs, {Andreas H.} and Michel Bottlaender and David Brooks and Carroll, {Michael A.} and Sylvie Chalon and Paul Edison and Anthony Gee and Alexander Gerhard and Christer Halldin and Oskar Hansson and Karl Herholz and Herth, {Matthias M.} and Rainer Hinz and Jacobs, {Andreas H.} and Knudsen, {Gitte M.} and Bertrand Kuhnast and Lammertsma, {Adriaan A.} and Francisco Lopez-Picon and Moresco, {Rosa Maria} and Agneta Nordberg and Sabina Pappata and Daniela Perani and Rinne, {Juha O.} and Elena Rodriguez-Vieitez and Santiago-Ribeiro, {Marie Joao} and Turkheimer, {Federico E.} and {Van Laere}, Koen and Andrea Varrone and Johnny Vercouillie and Windhorst, {Albert D.} and Alexandra Winkeler",
year = "2019",
month = "8",
doi = "10.1016/j.jalz.2019.02.004",
language = "English",
volume = "15",
pages = "1081--1103",
journal = "Alzheimers & dementia",
issn = "1552-5260",
publisher = "ELSEVIER SCIENCE INC",
number = "8",

}

RIS

TY - JOUR

T1 - A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies

AU - Partners IMBI Project

AU - Perani, Daniela

AU - Iaccarino, Leonardo

AU - Lammertsma, Adriaan A.

AU - Windhorst, Albert D.

AU - Edison, Paul

AU - Boellaard, Ronald

AU - Hansson, Oskar

AU - Nordberg, Agneta

AU - Jacobs, Andreas H.

AU - Bottlaender, Michel

AU - Brooks, David

AU - Carroll, Michael A.

AU - Chalon, Sylvie

AU - Edison, Paul

AU - Gee, Anthony

AU - Gerhard, Alexander

AU - Halldin, Christer

AU - Hansson, Oskar

AU - Herholz, Karl

AU - Herth, Matthias M.

AU - Hinz, Rainer

AU - Jacobs, Andreas H.

AU - Knudsen, Gitte M.

AU - Kuhnast, Bertrand

AU - Lammertsma, Adriaan A.

AU - Lopez-Picon, Francisco

AU - Moresco, Rosa Maria

AU - Nordberg, Agneta

AU - Pappata, Sabina

AU - Perani, Daniela

AU - Rinne, Juha O.

AU - Rodriguez-Vieitez, Elena

AU - Santiago-Ribeiro, Marie Joao

AU - Turkheimer, Federico E.

AU - Van Laere, Koen

AU - Varrone, Andrea

AU - Vercouillie, Johnny

AU - Windhorst, Albert D.

AU - Winkeler, Alexandra

PY - 2019/8

Y1 - 2019/8

N2 - Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

AB - Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

KW - PET molecular imaging

KW - Radiotracers

KW - Protheinopathies

KW - Amyloid

KW - Tau

KW - Neuroinflammation

KW - AMYOTROPHIC-LATERAL-SCLEROSIS

KW - ALZHEIMERS ASSOCIATION WORKGROUPS

KW - MILD COGNITIVE IMPAIRMENT

KW - PITTSBURGH COMPOUND-B

KW - FRONTOTEMPORAL LOBAR DEGENERATION

KW - 18-KDA TRANSLOCATOR PROTEIN

KW - CEREBRAL AMYLOID ANGIOPATHY

KW - PET TRACER F-18-AV-1451

KW - IN-VIVO

KW - TAU-PET

U2 - 10.1016/j.jalz.2019.02.004

DO - 10.1016/j.jalz.2019.02.004

M3 - Article

VL - 15

SP - 1081

EP - 1103

JO - Alzheimers & dementia

JF - Alzheimers & dementia

SN - 1552-5260

IS - 8

ER -

ID: 97124742